{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"16.7"},{"groupId":"OG003","value":"25.0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"28.6"},{"groupId":"OG007","value":"100"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"44.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"7"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"4"},{"groupId":"OG009","value":"9"}],"units":"Participants"}],"description":"Percentage of participants with dose limiting toxicity were reported.","groups":[{"description":"Participants received 45 mg LTT462 once QD as oral capsules.","id":"OG000","title":"LTT462 45 mg QD"},{"description":"Participants received 100 mg LTT462 QD as oral capsules.","id":"OG001","title":"LTT462 100 mg QD"},{"description":"Participants received 150 mg LTT462 QD as oral capsules.","id":"OG002","title":"LTT462 150 mg QD"},{"description":"Participants received 200 mg LTT462 QD as oral capsules.","id":"OG003","title":"LTT462 200 mg QD"},{"description":"Participants received 300 mg LTT462 QD as oral capsules.","id":"OG004","title":"LTT462 300 mg QD"},{"description":"Participants received 400 mg LTT462 QD as oral capsules.","id":"OG005","title":"LTT462 400 mg QD"},{"description":"Participants received 450 mg LTT462 QD as oral capsules.","id":"OG006","title":"LTT462 450 mg QD"},{"description":"Participants received 600 mg LTT462 QD as oral capsules.","id":"OG007","title":"LTT462 600 mg QD"},{"description":"Participants received 150 mg LTT462 BID as oral capsules.","id":"OG008","title":"LTT462 150 mg BID"},{"description":"Participants received 200 mg LTT462 BID as oral capsules.","id":"OG009","title":"LTT462 200 mg BID"}],"paramType":"NUMBER","populationDescription":"The dose determining set included all participants from the safety set enrolled in the escalation part of the study who, during the first 28 days of dosing, had received at least 75 percent of the planned daily doses of LTT462 and had had sufficient safety evaluations, or had experienced a DLT.","reportingStatus":"POSTED","timeFrame":"Up to 2.8 years","title":"Percentage of Participants With Dose Limiting Toxicities (DLTs)","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}